Xtalpi Announced That They Are Embarking On A Strategic Collaboration With Ck Life Sciences, A Member Of The Ck Hutchison Group.Xtalpi And Ck Life Sciences Will Leverage Their Respective Expertise To Jointly Develop A Novel Ai Tumour Vaccine R&D Platform To Improve The Discovery And Design Capabilities Of Tumour Vaccines And Accelerate The Development Of More Vaccine Types. The Goal Of This Collaboration Is To Realize Precision Treatment For Patients Worldwide.According To Public Information, There Were Nearly 20 Million Newly Diagnosed Cancer Patients Worldwide In 2021, Of Which About 4.5 Million Cases Came From China. Many Cancer Types Lead To Detrimental Outcomes, With High Morbidity And Mortality, And There Remains A Large Unmet Clinical Need. Tumour Vaccines Targeting Different Tumour Neoantigens, Tumour-Associated Antigens (Taa) And Tumour-Specific Antigens (Tsa) In Patients Can Be Designed For Use As Immunotherapy, To Activate The Patient'S Own Specific Immune Responses.Currently, There Are Only Two Therapeutic Tumour Vaccines
